Literature DB >> 9365071

Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate).

E A Landsmeer-Beker1, G G Massa, P D Maaswinkel-Mooy, J J van de Kamp, S E Papapoulos.   

Abstract

UNLABELLED: Osteoporosis is an important feature of osteogenesis imperfecta (OI). So far, no effective medical treatment is available. We treated three boys with severe OI type III and vertebral deformities for 5-7 years with continuous oral administration of the bisphosphonate, olpadronate. Treatment resulted in a decreased number of bone fractures, an increased calcification of the long bones and an amelioration of vertebral shape. No side-effects were encountered.
CONCLUSION: These preliminary but long-term observations suggest that the bisphosphonate olpadronate may be a useful treatment for patients with OI and vertebral fractures. Bisphosphonates may be promising drugs for children with OI.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365071     DOI: 10.1007/s004310050715

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  9 in total

1.  The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment.

Authors:  C Robinson; N Baker; J Noble; A King; G David; D Sillence; P Hofman; T Cundy
Journal:  J Inherit Metab Dis       Date:  2002-12       Impact factor: 4.982

Review 2.  Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis.

Authors:  J Thornton; D M Ashcroft; M Z Mughal; R A Elliott; T W O'Neill; D Symmons
Journal:  Arch Dis Child       Date:  2006-05-11       Impact factor: 3.791

3.  Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial.

Authors:  Dieke H J Kok; Ralph J B Sakkers; Arieke J Janse; Hans E H Pruijs; Ab J Verbout; Rene M Castelein; Raoul H H Engelbert
Journal:  Eur J Pediatr       Date:  2007-02-17       Impact factor: 3.183

Review 4.  Osteogenesis imperfecta: practical treatment guidelines.

Authors:  F Antoniazzi; M Mottes; P Fraschini; P C Brunelli; L Tatò
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

5.  Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.

Authors:  E Aström; S Söderhäll
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

6.  Bisphosphonate treatment in the oim mouse model alters bone modeling during growth.

Authors:  S H Rao; K D Evans; A M Oberbauer; R B Martin
Journal:  J Biomech       Date:  2008-11-20       Impact factor: 2.712

Review 7.  The role of bisphosphonates in diseases of childhood.

Authors:  Tarak Srivastava; Uri S Alon
Journal:  Eur J Pediatr       Date:  2003-09-11       Impact factor: 3.183

8.  Current and emerging treatments for the management of osteogenesis imperfecta.

Authors:  Elena Monti; Monica Mottes; Paolo Fraschini; Piercarlo Brunelli; Antonella Forlino; Giacomo Venturi; Francesco Doro; Silvia Perlini; Paolo Cavarzere; Franco Antoniazzi
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

9.  Effects of WNT1 c.110 T>C and c.505G>T mutations on osteoblast differentiation via the WNT1/β-catenin signaling pathway.

Authors:  Bashan Zhang; Rong Li; Wenfeng Wang; Xueming Zhou; Beijing Luo; Zinian Zhu; Xibo Zhang; Aijiao Ding
Journal:  J Orthop Surg Res       Date:  2021-06-02       Impact factor: 2.359

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.